Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Will cholesteryl ester transfer protein inhibition succeed primarily by lowering low-density lipoprotein cholesterol? Insights from human genetics and clinical trials.

Kathiresan S.

J Am Coll Cardiol. 2012 Nov 13;60(20):2049-52. doi: 10.1016/j.jacc.2012.08.967. No abstract available.

2.

Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects.

Johannsen TH, Frikke-Schmidt R, Schou J, Nordestgaard BG, Tybjærg-Hansen A.

J Am Coll Cardiol. 2012 Nov 13;60(20):2041-8. doi: 10.1016/j.jacc.2012.07.045.

3.

Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?

Neeli H, Rader DJ.

Cardiol Clin. 2008 Nov;26(4):537-46. doi: 10.1016/j.ccl.2008.06.005. Review.

PMID:
18929230
4.

Treating high-density lipoprotein cholesterol: a return to inhibition of cholesteryl ester transfer protein?

Duriez P.

Curr Atheroscler Rep. 2008 Jun;10(3):177-9. No abstract available.

PMID:
18489843
5.

Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme.

Landmesser U, von Eckardstein A, Kastelein J, Deanfield J, Lüscher TF.

Eur Heart J. 2012 Jul;33(14):1712-5. doi: 10.1093/eurheartj/ehs182. No abstract available.

6.

Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.

Kappelle PJ, van Tol A, Wolffenbuttel BH, Dullaart RP.

Cardiovasc Ther. 2011 Dec;29(6):e89-99. doi: 10.1111/j.1755-5922.2010.00201.x. Review.

PMID:
20645987
7.

Structural and biophysical insight into cholesteryl ester-transfer protein.

Hall J, Qiu X.

Biochem Soc Trans. 2011 Aug;39(4):1000-5. doi: 10.1042/BST0391000. Review.

PMID:
21787337
8.

When good cholesterol turns bad: the evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein.

Oram JF, Heinecke JW.

Curr Atheroscler Rep. 2007 Dec;9(6):425-7. No abstract available.

PMID:
18377780
9.

CETP Inhibition: does the future look promising?

Toth PP.

Curr Cardiol Rep. 2011 Dec;13(6):559-65. doi: 10.1007/s11886-011-0218-x. Review.

PMID:
21909703
10.

Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP Inhibition as a Strategy to Reduce Cardiovascular Risk: The Pro Case.

Barter PJ, Nicholls SJ, Kastelein JJ, Rye KA.

Circulation. 2015 Aug 4;132(5):423-32. doi: 10.1161/CIRCULATIONAHA.114.014025. No abstract available.

11.

Cholesteryl ester transfer protein and its inhibition.

Weber O, Bischoff H, Schmeck C, Böttcher MF.

Cell Mol Life Sci. 2010 Sep;67(18):3139-49. doi: 10.1007/s00018-010-0418-3. Review.

PMID:
20556633
12.
13.

Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.

Niesor EJ.

Curr Opin Lipidol. 2011 Aug;22(4):288-95. doi: 10.1097/MOL.0b013e3283475e00. Review.

PMID:
21587074
14.

Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP as a Target to Lower CVD Risk: Suspension of Disbelief?

Hovingh GK, Ray KK, Boekholdt SM.

Circulation. 2015 Aug 4;132(5):433-40. doi: 10.1161/CIRCULATIONAHA.115.014026. No abstract available.

15.

Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?

Barter P, Rye KA.

Trends Pharmacol Sci. 2011 Dec;32(12):694-9. doi: 10.1016/j.tips.2011.07.004. Review.

PMID:
22088767
16.

JTT-705: is there still future for a CETP inhibitor after torcetrapib?

Rennings AJ, Stalenhoef A.

Expert Opin Investig Drugs. 2008 Oct;17(10):1589-97. doi: 10.1517/13543784.17.10.1589 . Review.

PMID:
18808319
17.

The role of CETP inhibition in dyslipidemia.

El Harchaoui K, van der Steeg WA, Stroes ES, Kastelein JJ.

Curr Atheroscler Rep. 2007 Aug;9(2):125-33. Review.

PMID:
17877921
18.

Cholesteryl ester transfer protein inhibition: a dysfunctional endothelium.

Westerterp M, Koetsveld J, Tall AR.

J Cardiovasc Pharmacol. 2010 May;55(5):456-8. doi: 10.1097/FJC.0b013e3181dc61d4. No abstract available. Erratum in: J Cardiovasc Pharmacol. 2010 Jul;56(1):110.

PMID:
20351566
19.

Perspective. The failure of cholesteryl ester transfer protein inhibitors: is it due to increased blood viscosity?

Sloop GD, Weidman JJ, St Cyr JA.

Ther Adv Cardiovasc Dis. 2015 Apr;9(2):32-5. doi: 10.1177/1753944714566427. No abstract available.

PMID:
25573766
20.

Cholesteryl ester transfer protein antagonism by drugs--a poor choice.

Sirtori CR, Mombelli G.

Clin Chem. 2010 Oct;56(10):1550-3. doi: 10.1373/clinchem.2010.147389. No abstract available.

Items per page

Supplemental Content

Support Center